Tamtam Try Tamtam free
Almirall logo

Almirall account plan

Medical Dermatology Solutions

At a glance

Almirall is a Barcelona-based pharmaceutical group focused on medical dermatology, with FY2025 net turnover of €1,108.1 million and 2,108 employees.

Almirall is a pharmaceutical group founded in 1944, headquartered in Barcelona and listed on the Spanish Stock Exchange (ticker ALM), that has refocused its strategy on skin health; its R&D centre is dedicated exclusively to skin health. Its growth comes from European medical dermatology (Ebglyss, Ilumetri, Wynzora, Klisyri), complemented by legacy respiratory, gastrointestinal, central nervous system, cardiovascular and musculoskeletal products. FY2025 net turnover was €1,108.1 million (+12.4%) and consolidated net profit €46.2 million, against €10.1 million in 2024. It had 2,108 employees at end-2025, 96% of them in Europe, and runs plants in Sant Andreu de la Barca, Sant Celoni (Spain) and Reinbek (Germany). The Gallardo family controls it through Grupo Plafin (44.3%) and Grupo Corporativo Landon (15.6%), and Carlos Gallardo Piqué is Chairman and CEO.

Business units

Strategic priorities

Leadership in European medical dermatology
European Dermatology net sales grew 25.6% in 2025 and remain the main growth engine; management targets more than EUR 300 million peak sales for Ilumetri and more than EUR 450 million for Ebglyss.
Mid-term growth and margin targets
A double-digit net sales CAGR between 2023 and 2030 and an EBITDA margin of around 25% by 2028; 9M 2026 EBITDA was already about 25% of net sales, two years ahead of the 2028 ambition.
Skin-health pipeline with global rights
Six PoC/Phase II programmes across five dermatological diseases, including hidradenitis suppurativa, alopecia areata, atopic dermatitis and pyoderma gangrenosum; the first readout is expected in the coming months, the rest during 2027 and early 2028.
External innovation and partnering
R&D keeps hypothesis generation in-house and partners for the modality, with deals such as CrystalO, Certest Biotec, Huaota and Wockhardt, and new offices in China.
Disciplined capital deployment
Management looks for selective bolt-on M&A and early-stage licensing that fit the medical dermatology strategy, while keeping a prudent financial approach.

Latest results

In the first nine months of 2026, net sales rose 8.3% to €889.2 MM and EBITDA rose 22.7% to €221.7 MM, a 24.9% margin against 22.0% a year earlier. European Dermatology grew 17.6% to €520.3 MM, with Ebglyss at €132.1 MM (+75.0%) and Ilumetri at €190.6 MM (+11.5%); Q3 was Ilumetri's best quarter since launch. Net income was €53.3 MM (+36.3%) and free cash flow EUR 83 million against EUR 42 million. FY2026 guidance of 9-12% net sales growth and €270-290 MM EBITDA was reiterated, with sales expected toward the mid-to-low end of the range and EBITDA toward the upper end. FY2026 results are due on 22 February 2027.

Investments and deals

R&D spend
R&D expenses were €138.2 million in 2025 (+11%) and about 12% of net sales in 9M 2026; Almirall has invested more than €1 billion in R&D over the last decade.
Licensing and research collaborations
In 2026 Almirall signed a collaboration and licensing deal with Certest Biotec (mRNA/LNP, rare skin diseases), a collaboration with Huaota, and a deal with CrystalO for ion-channel small molecules, and extended its partnership with the Barcelona Supercomputing Center on AI.
Bond refinancing
On 17 December 2025 Almirall issued €250 million of senior unsecured bonds at 3.75%, maturing on 15 June 2031; S&P raised the rating to BB+ and Moody's upgraded it to Ba1.
Milestone and ordinary capex
Investment capex for licensed-asset milestones will average about EUR 70-75 million a year, and ordinary capex about EUR 70-80 million in 2026.
Portfolio pruning
Divestment of Algidol and the Sekisan licence in Spain in January 2025 (€12 million collected) and the Actithiol divestment.

Challenges and risks

European price and reimbursement pressure
Price cuts, reimbursement conditions and contributions to health systems may grow with government budget deficits; the German healthcare reform could cost 1% to 2.5% of revenue from 2027, per market estimates.
Legacy and US portfolio decline
The legacy non-dermatology portfolio fell 4.6% over nine months of 2026, and US sales declined as Cordran Tape, Tazorac and Aczone face generics and Seysara more competition.
Pipeline risk
The report names an R&D pipeline that is not balanced or differentiated enough as a risk, with the first PoC readouts only starting around the end of 2026.
Supply, cyber and talent risks
Supply shortages from geopolitical volatility or climate risks, cyberattacks and difficulty attracting and retaining talent are named among the principal risks.

What leadership says

“Our solid results in Q3 are in line with our expectations and our long-term growth trajectory and are being led by the sustained growth of our European Dermatology business and our biologics.”

Carlos Gallardo, Chairman and CEO · Almirall 9M 2026 Results, 9 November 2026

“we remain disciplined but active on capital deployment”

Carlos Gallardo, Chairman and CEO · Almirall 9M 2026 earnings call, 9 November 2026

“We are committed to shaping leadership in medical dermatology in Europe, turning innovation into growth, and delivering lasting value for patients and shareholders.”

Carlos Gallardo Piqué, Chairman and CEO · Almirall Full Year 2025 earnings call, 23 February 2026

“There is still a lot of uncertainty about how this will land.”

Carlos Gallardo, Chairman and CEO · On the German healthcare reform, Almirall 9M 2026 earnings call, 9 November 2026

Where a supplier can help

Biologics launch and market access in Europe
The Ebglyss and Ilumetri peak-sales targets and European price pressure create needs for market access, real-world evidence and HCP engagement services across launch countries.
Clinical development services
Six PoC/Phase II programmes, a Phase III in nummular eczema and a Phase IIIb in face and neck atopic dermatitis call for CRO, patient recruitment and trial data capacity.
Discovery and AI partnerships
The partner-for-modality R&D model and the extended AI collaboration with the Barcelona Supercomputing Center open doors for discovery platforms and computational biology providers.
Manufacturing and supply resilience
Supply shortages are a named risk across plants in Spain and Germany and third-party manufacturers, pointing to supply-chain visibility and contract manufacturing offers.
Cybersecurity
Cyberattacks are listed among the principal risks of a group with subsidiaries across Europe, the United States and China.

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like Almirall?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about Almirall

What does Almirall do?

Almirall is a Barcelona-based pharmaceutical group focused on skin health. It sells dermatology treatments such as Ebglyss, Ilumetri, Wynzora and Klisyri, mainly in Europe, alongside legacy products in other therapeutic areas.

What is Almirall's revenue?

FY2025 net turnover was €1,108.1 million (+12.4%), the first year above EUR 1 billion. In the first nine months of 2026 net sales were €889.2 MM, up 8.3%.

How many employees does Almirall have?

Almirall had 2,108 employees at end-2025, 96% in Europe and 4% in the United States, with 1,349 in Spain.

Who leads Almirall?

Carlos Gallardo Piqué is Chairman and CEO, with Jon Garay as CFO and Karl Ziegelbauer as Chief Scientific Officer.

What is Almirall's strategy?

It aims at leadership in medical dermatology in Europe, growing its biologics, building a skin-health pipeline with global rights through partnerships, and pursuing selective bolt-on M&A.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)